What Makes Glaukos Corporation (GKOS) a Compelling Stock?

2 months ago 18

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

Soumya Eswaran

Tue, Apr 8, 2025, 6:41 AM 3 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Small Cap Growth Strategy” archetypal 4th 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The banal marketplace show successful the archetypal 4th of 2025 was volatile, pursuing the archetypal “animal spirits” post-election rally. The strategy surpassed its benchmark with the enactment of caller ideas, reorienting efforts, and tailwinds successful respective industries contempt volatility and uncertainty. Given the gait of large argumentation changes, the steadfast expects ongoing volatility arsenic the effects of tariffs and policymaking person clouded visibility. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its archetypal 4th 2025 capitalist letter, ClearBridge Small Cap Growth Strategy emphasized stocks specified arsenic Glaukos Corporation (NYSE:GKOS). Glaukos Corporation (NYSE:GKOS) is an ophthalmic pharmaceutical and aesculapian exertion company. The one-month instrumentality of Glaukos Corporation (NYSE:GKOS) was -11.98%, and its shares mislaid 15.04% of their worth implicit the past 52 weeks. On April 7, 2025, Glaukos Corporation (NYSE:GKOS) banal closed astatine $86.07 per stock with a marketplace capitalization of $4.869 billion.

ClearBridge Small Cap Growth Strategy stated the pursuing regarding Glaukos Corporation (NYSE:GKOS) successful its Q1 2025 capitalist letter:

"We continued to make a fig of compelling caller ideas, adding 5 caller investments that we inactive held astatine 4th end: Glaukos Corporation (NYSE:GKOS), Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron.

A doc examining a patient's eyes with an ophthalmic aesculapian device.

Glaukos Corporation (NYSE:GKOS) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge money portfolios held Glaukos Corporation (NYSE:GKOS) astatine the extremity of the 4th fourth compared to 32 successful the 3rd quarter. In 2024, Glaukos Corporation's (NYSE:GKOS) consolidated nett income grew 22% twelvemonth implicit twelvemonth to $383.5 million. While we admit the imaginable of Glaukos Corporation (NYSE:GKOS) arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns, and doing truthful wrong a shorter timeframe. If you are looking for an AI banal that is arsenic promising arsenic NVIDIA but that trades astatine little than 5 times its earnings, cheque retired our study astir the cheapest AI stock.